Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast

  Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results
  Conference Call and Webcast

        -Special Meeting of Shareholders scheduled for April 26, 2013-

Business Wire

MORRISVILLE, N.C. -- March 13, 2013

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that the Company
plans to report third quarter fiscal year 2013 financial results on Form 10-Q
on Monday, March 18, 2013. Oxygen’s President and Chief Financial Officer
Michael Jebsen will host a conference call and live webcast to discuss the
results on Tuesday, March 19, 2013, at 11 a.m. EDT.

To access the live teleconference, dial (866) 277-1184 (U.S. and Canada) or
(617) 597-5360 (international.) The participant pass code is 10084976. A live
webcast will be available on our web site
http://www.oxybiomed.com/investors.htm.

A replay of the webcast will be available on the Oxygen website, or by phone
for a limited time. To access the replay by phone, call (888) 286-8010 (U.S.
and Canada) or (617) 801-6888 (international). The pass code for the replay is
10065352.

In addition, the company announced that it will hold a Special Meeting of
Shareholders on April 26, 2013. A preliminary proxy on Form Pre 14A was filed
with the Securities and Exchange Commission on March 12. To access a copy of
the Form Pre 14A, click here and then click the SEC Filings tab.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that
efficiently deliver oxygen to tissues in the body. The company has developed a
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte^®
that is currently in clinical and preclinical studies for intravenous delivery
for indications such as traumatic brain injury, decompression sickness and
stroke. The company is also developing PFC-based creams and gels for topical
delivery to the skin for dermatologic conditions and potentially wound care.
In addition, the Company has commercialized its Dermacyte^® line of skin care
cosmetics for the anti-aging market.

Contact:

Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-2112
Senior Vice President, Corporate Communications & Investor Relations
 
Press spacebar to pause and continue. Press esc to stop.